Research / RMR / Fundamental state Inspectable configuration
State dimensions Filing 0001644378-26-000014 General Corporate
Operating cash generation 100th Own-history percentile · N=14
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
116.16% · OPTIONAL · VALID
Revenue growth 50th Own-history percentile · N=10
Evidence method Yoy · gp.fundamentals.revenue
-7.63% · CORE · VALID
Operating margin 57th Own-history percentile · N=14
Evidence method Level · gp.fundamentals.operating_margin
16.75% · CORE · VALID
SBC intensity 100th Own-history percentile · N=14
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
7.20% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 12 states History building
Sep 30, 2023 0/5 normalized Level 3 Dec 31, 2023 0/6 normalized Level 3 Mar 31, 2024 0/6 normalized Level 3 Jun 30, 2024 0/6 normalized Level 3 Sep 30, 2024 4/5 normalized Level 3 Dec 31, 2024 4/5 normalized Level 3 Mar 31, 2025 4/5 normalized Level 3 Jun 30, 2025 3/4 normalized Level 3 Sep 30, 2025 4/5 normalized Level 3 Dec 31, 2025 4/4 normalized Level 3 Mar 31, 2026 4/4 normalized Level 3 Jun 30, 2026 4/4 normalized Level 3 Period transition
What moved in the state? Cash Generation Increased
Previous 16.11%
Current 116.16%
Delta 100.05% Growth Decreased
Previous 40.76%
Current -7.63%
Delta -48.40% Profitability Decreased
Previous 48.10%
Current 16.75%
Delta -31.34% Sbc Intensity Increased
Previous 2.93%
Current 7.20%
Delta 4.27% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.